445 related articles for article (PubMed ID: 30008616)
1. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.
Battaglin F; Naseem M; Puccini A; Lenz HJ
Cancer Cell Int; 2018; 18():99. PubMed ID: 30008616
[TBL] [Abstract][Full Text] [Related]
2.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
3. Progress and challenges in gastroesophageal cancer.
Serra O; Smyth EC; Lordick F
Curr Probl Cancer; 2020 Dec; 44(6):100590. PubMed ID: 32451067
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapies in Advanced Gastric Cancer.
Patel TH; Cecchini M
Curr Treat Options Oncol; 2020 Jul; 21(9):70. PubMed ID: 32725377
[TBL] [Abstract][Full Text] [Related]
5. Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients.
Nshizirungu JP; Bennis S; Mellouki I; Sekal M; Benajah DA; Lahmidani N; El Bouhaddouti H; Ibn Majdoub K; Ibrahimi SA; Celeiro SP; Viana-Pereira M; Munari FF; Ribeiro GG; Duval V; Santana I; Reis RM
Dis Markers; 2021; 2021():9980410. PubMed ID: 34367379
[TBL] [Abstract][Full Text] [Related]
6. HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies.
Ieni A; Cardia R; Pizzimenti C; Zeppa P; Tuccari G
J Pers Med; 2020 Feb; 10(1):. PubMed ID: 32098203
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets.
Kankeu Fonkoua L; Yee NS
Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29522457
[TBL] [Abstract][Full Text] [Related]
10. Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma.
Salati M; Caputo F; Bocconi A; Cerri S; Baldessari C; Piacentini F; Dominici M; Gelsomino F
Front Oncol; 2022; 12():993573. PubMed ID: 36212393
[TBL] [Abstract][Full Text] [Related]
11. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
Zhao D; Klempner SJ; Chao J
J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y; Kawazoe A; Lordick F; Janjigian YY; Shitara K
Nat Rev Clin Oncol; 2021 Aug; 18(8):473-487. PubMed ID: 33790428
[TBL] [Abstract][Full Text] [Related]
13. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.
Tirino G; Pompella L; Petrillo A; Laterza MM; Pappalardo A; Caterino M; Orditura M; Ciardiello F; Galizia G; De Vita F
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205505
[TBL] [Abstract][Full Text] [Related]
14. Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.
Sato Y; Okamoto K; Kawano Y; Kasai A; Kawaguchi T; Sagawa T; Sogabe M; Miyamoto H; Takayama T
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510761
[TBL] [Abstract][Full Text] [Related]
15. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.
Nagaraja AK; Kikuchi O; Bass AJ
Cancer Discov; 2019 Dec; 9(12):1656-1672. PubMed ID: 31727671
[TBL] [Abstract][Full Text] [Related]
16. Current and Future Biomarkers in Esophagogastric Adenocarcinoma.
Sappenfield R; Mehlhaff E; Miller D; Ebben JE; Uboha NV
J Gastrointest Cancer; 2024 Jan; ():. PubMed ID: 38280174
[TBL] [Abstract][Full Text] [Related]
17. HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology.
Machado-Neves R; Vale J; Eloy C; Polónia A
Pathol Res Pract; 2020 Sep; 216(9):153090. PubMed ID: 32825958
[TBL] [Abstract][Full Text] [Related]
18. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
[TBL] [Abstract][Full Text] [Related]
19. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
20. Current developments in gastric cancer: from molecular profiling to treatment strategy.
Alsina M; Arrazubi V; Diez M; Tabernero J
Nat Rev Gastroenterol Hepatol; 2023 Mar; 20(3):155-170. PubMed ID: 36344677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
